Enhancer of zeste homolog 2 (EZH2) is a catalytic component of the polycomb repressive complex 2 (PRC2) which reduces gene expression via trimethylation of a lysine residue of histone 3 (H3K27me3). Expression of EZH2 has not been assessed systematically in mantle cell lymphoma (MCL). Expression of EZH2 was assessed by immunohistochemistry in 166 patients with MCL. We also assessed other PRC2 components and H3K27me3. Fifty-seven (38%) of MCL patients were positive for EZH2 using 40% cutoff. EZH2 expression was associated with aggressive histologic variants (65% vs. 29%, p < 0.001), high Ki-67 proliferation rate (median, 72% vs. 19%, p < 0.001), and p53 overexpression (43% vs. 2%, p < 0.001). EZH2 expression did not correlate with expression of other PRC2 components (EED and SUZ12), H3K27me3, MHC-I, and MHC-II. Patients with EZH2 expression (EZH2+) had a poorer overall survival (OS) compared with patients without EZH2 expression (EZH2−) (median OS: 3.9 years versus 9.4 years, respectively, p < 0.001). EZH2 expression also predicted a poorer prognosis in MCL patients with classic histology (median OS, 4.6 years for EZH2+ and 9.6 years for EZH2-negative, respectively, p < 0.001) as well as aggressive histology (median OS, 3.7 years for EZH2+ and 7.9 years for EZH2-negative, respectively, p = 0.046). However, EZH2 expression did not independently correlate with overall survival in a multivariate analysis. Gene expression analysis and pathway enrichment analysis demonstrated a significant enrichment in cell cycle and mitotic transition pathways in MCL with EZH2 expression. EZH2 expression detected by immunohistochemistry is present in 38% of MCL cases and it is associated with high proliferation rate, p53 overexpression, aggressive histologic variants, and poorer OS. Based on gene expression profiling data, EZH2 expression could potentiate cell cycle machinery in MCL. These data suggest that assessment of EZH2 expression could be useful to stratify MCL patients into low- and high-risk groups.
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
All data generated or analyzed during this study are included in this published article.
Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375–2390 (2016).
Geisler, C. H. et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 115, 1530–1533 (2010).
Geisler, C. H. et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem-cell support: still very long survival but late relapses do occur. Br. J. Haematol. 158, 355–362 (2012).
Romaguera, J. E. et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br. J. Haematol. 150, 200–208 (2010).
Cao, Q. et al. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 20, 187–199 (2011).
Ezponda, T. & Licht, J. D. Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination. Clin. Cancer Res. 20, 5001–5008 (2014).
Pasini, D. et al. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic Acids Res. 38, 4958–4969 (2010).
Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624–629 (2002).
Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. U.S.A. 100, 11606–11611 (2003).
Bodor, C. et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 122, 3165–3168 (2013).
Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181–185 (2010).
Morschhauser, F. et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 21, 1433–1442 (2020).
Bea, S. et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc. Natl Acad. Sci. U.S.A. 110, 18250–18255 (2013).
Wu, C. et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. Oncotarget 7, 38180–38190 (2016).
Zhang, J. et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood 123, 2988–2996 (2014).
Meissner, B. et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood 121, 3161–3164 (2013).
Kridel, R. et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 119, 1963–1971 (2012).
Zhao, S. et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am. J. Hematol. 95, 623–629 (2020).
Jain, P. et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br. J. Haematol. 183, 578–587 (2018).
Jain, P. et al. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv. 4, 1038–1050 (2020).
Pararajalingam, P. et al. Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. Blood 136, 572–584 (2020).
Nadeu, F. et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood 136, 1419–1432 (2020).
Kim, D. H. et al. Mantle cell lymphoma involving skin: a clinicopathologic study of 37 cases. Am. J. Surg. Pathol. 43, 1421–1428 (2019).
van Kemenade, F. J. et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97, 3896–3901 (2001).
Abd Al Kader, L. et al. In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2. Virchows Arch. 463, 697–711 (2013).
Visser, H. P. et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br. J. Haematol. 112, 950–958 (2001).
Hoster, E. et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111, 558–565 (2008).
World Medical, A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310, 2191–2194 (2013).
Hoster, E. et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network. J. Clin. Oncol. 34, 1386–1394 (2016).
Aukema, S. M. et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood 131, 417–420 (2018).
Ennishi, D. et al. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov. 9, 546–563 (2019).
Tian, X., Pelton, A., Shahsafaei, A. & Dorfman, D. M. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas. Mod. Pathol. 29, 1050–1057 (2016).
Romanchikova, N. & Trapencieris, P. Wedelolactone targets EZH2-mediated Histone H3K27 methylation in mantle cell lymphoma. Anticancer Res. 39, 4179–4184 (2019).
Kanduri, M. et al. A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma. Epigenetics 8, 1280–1288 (2013).
Demosthenous, C. et al. Deregulation of polycomb repressive complex-2 in mantle cell lymphoma confers growth advantage by epigenetic suppression of cdkn2b. Front. Oncol. 10, 1226 (2020).
Rao, R. C., Chan, M. P., Andrews, C. A. & Kahana, A. EZH2, proliferation rate, and aggressive tumor subtypes in cutaneous basal cell carcinoma. JAMA Oncol. 2, 962–963 (2016).
Bachmann, I. M. et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24, 268–273 (2006).
Shiogama, S., Yoshiba, S., Soga, D., Motohashi, H. & Shintani, S. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration. Anticancer Res. 33, 4309–4317 (2013).
Zhang, H. M., Chen, S. Q. & Yao, S. Z. Expression and clinical implications of enhancer of Zeste homolog 2 and p53 protein in squamous cell carcinoma and precancerous lesions in the cervix. Genet. Mol. Res. 15, gmr.15027408 (2016).
Pietersen, A. M. et al. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res. 10, R109 (2008).
Zhao, Y. et al. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J. 38, e99599 (2019).
McCabe, M. T. et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl Acad. Sci. U.S.A. 109, 2989–2994 (2012).
Yap, D. B. et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451–2459 (2011).
Kim, E. et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23, 839–852 (2013).
Lee, S. T. et al. Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. Mol. Cell 43, 798–810 (2011).
Yan, J. et al. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood 121, 4512–4520 (2013).
Mok, M. T. et al. CCRK is a novel signalling hub exploitable in cancer immunotherapy. Pharmacol. Ther. 186, 138–151 (2018).
Shen, T. & Huang, S. The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med. Chem. 12, 631–639 (2012).
Papakonstantinou, N. et al. The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia. Oncotarget 7, 35946–35959 (2016).
This study was supported by MD Anderson’s Histopathology Core Lab (RHCL), Award Number 2P30CA016672-38 from the NIH National Cancer Institute. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
This study was supported by UT MDACC institutional grant to C.Y.O.
The authors declare no competing interests.
Ethics approval and consent to participate
This study was approved by the Institutional Review Board (protocol 2019-1191) at the University of Texas MD Anderson Cancer Center, which waived the requirement of written informed consent.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Martinez-Baquero, D., Sakhdari, A., Mo, H. et al. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. Mod Pathol (2021). https://doi.org/10.1038/s41379-021-00885-9